GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Degree of Financial Leverage

Apollon Formularies (AQSE:APOL) Degree of Financial Leverage : 0.00 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Apollon Formularies's Degree of Financial Leverage for the quarter that ended in Jun. 2023 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Apollon Formularies's Degree of Financial Leverage or its related term are showing as below:

AQSE:APOL's Degree of Financial Leverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

Apollon Formularies Degree of Financial Leverage Historical Data

The historical data trend for Apollon Formularies's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Degree of Financial Leverage Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.24

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.26 0.24 2.00 -

Competitive Comparison of Apollon Formularies's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Degree of Financial Leverage falls into.



Apollon Formularies Degree of Financial Leverage Calculation

Apollon Formularies's Degree of Financial Leverage for the quarter that ended in Jun. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.001 (Jun. 2023) / -0.001 (Jun. 2022) - 1 )/( -0.403 (Jun. 2023) / -1.047 (Jun. 2022) - 1 )
=0/-0.6151
=0.00***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Apollon Formularies  (AQSE:APOL) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Apollon Formularies Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013